opicinumab

03/01/2017 - "Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial."
03/01/2017 - "We therefore assessed the safety and tolerability, and efficacy of opicinumab given soon after a first acute optic neuritis episode. "
01/01/2019 - "Initial Impairment and Recovery of Vision-Related Functioning in Participants With Acute Optic Neuritis From the RENEW Trial of Opicinumab."
12/01/2018 - "Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential."
10/01/2018 - "RENEW assessed the efficacy/safety of opicinumab versus placebo in participants with a first unilateral acute optic neuritis (AON) episode. "

01/01/2019 - "Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial."
01/01/2019 - "We aimed to assess the safety and efficacy of opicinumab in patients with relapsing multiple sclerosis. "
07/01/2020 - "Opicinumab: is it a potential treatment for multiple sclerosis?"
01/01/2020 - "The anti-LINGO-1 antibody Li81 (opicinumab), which blocks LINGO-1 function and shows robust remyelinating activity in animal models, is currently being investigated in a Phase 2 clinical trial as a potential treatment for individuals with relapsing forms of multiple sclerosis (AFFINITY: clinical trial.gov number NCT03222973). "
08/01/2014 - "To evaluate the safety, tolerability, and pharmacokinetics (PK) of BIIB033 (anti-LINGO-1 monoclonal antibody) in healthy volunteers and participants with multiple sclerosis (MS). "

11/01/2017 - "Anti lingo 1 (opicinumab) a new monoclonal antibody tested in relapsing remitting multiple sclerosis."
01/01/2019 - "Participants (aged 18-58 years) with relapsing multiple sclerosis (relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis with relapses) were randomised in a 1:2:2:2:2 ratio by an interactive voice and web response system to opicinumab 3 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg, or placebo. "

03/01/2017 - "Treatment-related serious adverse events were reported in three (7%) of 41 participants in the opicinumab group (hypersensitivity [n=2], asymptomatic increase in transaminase concentrations [n=1]) and none of the participants in the placebo group. "
01/01/2019 - "Serious adverse events reported as related to treatment were urinary tract infection in one (1%) participant in the the placebo group, suicidal ideation and intentional overdose in one (1%) participant in the 30 mg/kg opicinumab group, bipolar disorder in one (1%) participant in the 100 mg/kg opicinumab group, and hypersensitivity in four (4%) participants in the 100 mg/kg opicinumab group. "

01/01/2019 - "Previous findings suggested that opicinumab treatment might enhance remyelination in patients with CNS demyelinating diseases. "
08/01/2014 - "The emerging safety, tolerability, and PK of BIIB033 support advancing BIIB033 into phase II clinical development as a potential treatment for CNS demyelination disorders. "